An evaluation of the effects and safety of Zuogui pill for treating osteoporosis: Current evidence for an ancient Chinese herbal formula

Abstract

The aim of this study is to systematically evaluate existing evidence of the Chinese herbal formula, Zuogui pill (ZGP), for the treatment of osteoporosis. A systematic literature search was performed in six electronic databases. The authors independently extracted data in pairs and evaluated the risk of bias. A total of 221 articles were identified initially, of which 12 relevant studies were enrolled. The primary outcome was fracture incidence and bone mineral density (BMD) at different sites. Bone metabolism markers, clinical symptoms, quality of life, and adverse events or adverse drug reactions (ADRs) were secondary outcomes. The results showed that ZGP, combined with anti‐osteoporosis drugs, significantly increased BMD at the lumbar spine, Ward's area, and total hip. In terms of markers for improved bone metabolism, ZGP plus conventional drugs dramatically improved the levels of alkaline phosphatase, bone Gla protein, bone alkaline phosphatase, and tartrate‐resistant acid phosphatase. Gastrointestinal discomfort, dizziness, and fatigue were found in the combined therapy group. Although the results indicate that ZGP is a potential candidate for osteoporosis, evidence remains insufficient. Further rigorously designed and high‐quality trials with a larger sample size are warranted to verify the current conclusions.

The Efficacy and Safety of Chinese Herbal Medicine Xianling Gubao Capsule Combined With Alendronate in the Treatment of Primary Osteoporosis: A Systematic Review and Meta-Analysis of 20 Randomized Controlled Trials

“…The findings of another systematic review and meta-analysis indicated that Liuwei Dihuang pill is effective in improving BMD of hip and lumbar spine and alleviating pain in patients with postmenopausal OP (Wang, et al, 2020a). Besides, the findings of a previous review showed that Zuogui pill combined with anti-OP drugs remarkably increased BMD at different sites and improved the bone metabolism markers for treating OP (Li, et al, 2020). Besides, most of our findings were congruent with the data of An et al (An, et al, 2019).…”

Kidney tonifying traditional Chinese medicine: Potential implications for the prevention and treatment of osteoporosis

“…It controls OP by regulating multiple signaling pathways and has the functions of increasing bone production, stabilizing bone structure, enhancing OB proliferation and differentiation, and inhibiting OC. In addition, Drynariae Rhizoma can increase the body’s absorption of calcium, promote calcium transport into bone, strengthen bone mineralization, maintain the balance of bone remodeling; regulate the metabolic level of the hypothalamic-pituitary-gonadal axis, improve endocrine function, inhibit the synthesis and secretion of inflammatory factors in bone metabolism, and have a potential anti-osteoporosis effect ( Zhao et al, 2020a ; Li J et al, 2021 ). Flavonoids are the main components of Drynariae Rhizoma in the prevention and treatment of OP.…”

Quantitative Proteomics Revealed the Pharmacodynamic Network of Bugu Shengsui Decoction Promoting Osteoblast Proliferation

“…Recently, Traditional Chinese medicine shows obvious curative effects on OP, which significantly increases bone density, reduces the incidence of fragility fractures, and plays anti-inflammatory and analgesic roles in OP patients (7)(8)(9). Especially, Bugu Shengsui Decoction (BGSSD), a traditional Chinese medicine compound formula, is applied to treat OP in clinical practice.…”